We have presented pre-clinical data with ALN-CC5, an RNAi therapeutic for the treatment of complement-mediated diseases, at the 6th
International Conference on Complement Therapeutics being held June 18 – 23, 2013. The data showed that administration of a GalNAc-siRNA conjugate targeting the C5 component of complement resulted in potent, dose-dependent, and durable silencing of C5 liver mRNA, knockdown of C5 serum protein levels, and inhibition of complement-mediated hemolytic activity in rodents.
[spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/Alnylam-ALN-CC5-ComplementTxConf-130620.pdf" type="(0.8 MB PDF)"] View our presentation [/spotlight-link]
[spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=772627" type=" "] Read our press release[/spotlight-link]